// App-Quantinova.ai

3692 : Phase I/II Trial of Ofatumumab/Lenalidamide for Patients with Relasped/Refractory B-Cell Non-Hodgkin Lymphoma: High Response Rate in Indolent Lymphoma

Researchers

Presenter

  • Fausto R. Loberiza Jr

Principal Investigators

  • R. Gregory Bociek

  • Philip Bierman

  • James O. Armitage

Medical Centers

  • Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE

  • Department of Internal Medicine, Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Chronic Lymphocytic Leukemia

  • B-Cell Non-Hodgkin Lymphoma

  • Non-Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Mantle cell lymphoma

  • Follicular lymphoma

  • Acute renal failure

  • Hodgkin's Lymphoma

  • B cell lymphomas

  • Renal insufficiency

  • Neutropenia

  • Venous thrombosis

  • Lymphomas

  • Stroke

Biomarkers

  • Lactate dehydrogenase

Drug/Treatment

  • Lenalidomide

  • ofatumumab Intravenous

  • Aspirin

  • Albyl-E

Outcome

  • N/A

Study Design

  • fixed dose

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved